Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...